loss and improves both insulin resistance and glucose tolerance in mouse models of obesitydiabetes [ 3 , 4 ] . Despite the therapeutic potential for (pGlu-Gln)-CCK-8, there is a lack of information on its central eff ects. Therefore, the current study examined the consequence of twice daily (pGlu-Gln)-CCK-8 administration on metabolic status and the expression of key hypothalamic genes involved in energy balance in high fat mice.
Introduction

▼
Cholecystokinin (CCK), a gut peptide secreted by endocrine I-cells in response to feeding, regulates short-term energy balance through stimulation of central satiety [ 1 ] . CCK exerts this eff ect through binding to specifi c CCK 1 Rs on vagal aff erent neurons, activating central pathways involved in energy regulation [ 1 ] . Vagal aff erents are essential to CCK-induced satiety, as demonstrated through studies displaying an increase in vagal aff erent discharge after peripheral CCK injection, or reduction in satiety following surgical destruction of peripheral vagal terminals [ 2 ] . Notably, these vagal aff erents innervate neurons on the nucleus of the tractus solitaries (NTS) that terminate in the hypothalamus [ 1 ] . Accumulating evidence suggests that sustained CCK 1 R activation is a potential therapeutic option for obesity and related metabolic disease. Thus, we have recently developed the potent and stable CCK 1 R agonist, (pGlu-Gln)-CCK-8, an enzymatically stable CCK-8 analogue, with a signifi cantly prolonged biological half-life [ 3 ] . We have shown that (pGlu-Gln)-CCK-8 causes sustained weight 
In vivo studies
Over a 16-day period, high fat mice on a reversed light cycle (lights off between 09:30-21:30 h) received twice daily i.p. injections (09:00 and 17:00 h) of either saline vehicle (0.9 % (w/v), NaCl) or (pGlu-Gln)-CCK-8 (25 nmol/kg body wt). Body weight, total accumulated food intake, nonfasting plasma glucose and insulin concentrations were recorded on day 16. In addition, at the end of the study, i.p. glucose tolerance (18 mmol/kg body wt) and insulin sensitivity (20 U/kg body wt) tests were performed.
Gene expression
On day 16, hypothalamus tissue (n = 6) was excised and immediately snap-frozen in liquid nitrogen and stored at − 80 °C before RNA extraction for gene expression analysis. Briefl y, total RNA was isolated and purifi ed using QIAzol lysis reagent (Qiagen, West Sussex, UK) and RNA concentration determined from the absorbance at 260 nm. First-strand cDNA was synthesized using 2 μg of total RNA at 42 °C for 50 min in the presence of 0.5 μg oligo dT(12-18) primer, 10 mM dNTP and 200 U Superscript II reverse transcriptase (Invitrogen, Paisley, UK) in a fi nal volume of 20 μl using a GeneStorm GS1 Thermal Cycler (Gene Technologies Ltd, Essex, UK). Genes were amplifi ed using specifi c primers for Neuropeptide Y (NPY), proopiomelanocortin (POMC), melanocortin receptor 4 (MC4R), leptinR, CCK 1 R, glucagon-like peptide-1 (GLP-1)R and β-actin (Atcb 
Statistical analysis
Results are presented as mean ± SEM. Groups of data were compared using ANOVA and unpaired Student's t -test. Diff erences were considered signifi cant if p < 0.05. 
Results
▼
Eff ects of (pGlu-Gln)-CCK-8 on hypothalamic gene expression in high fat fed mice
NPY expression was signifi cantly (p < 0.05) enhanced in (pGluGln)-CCK-8-treated mice compared to high fat and lean control mice ( • ▶ Fig. 1a ). In addition, there was a signifi cant decrease Fig. 1d-f ).
Discussion
▼
In harmony with previous observations [ 3 , 4 ] , twice daily administration of (pGlu-Gln)-CCK-8 to high fat fed mice resulted in a marked improvement in glucose homeostasis and insulin sensitivity. Decreased accumulated energy intake was also observed in the current study, together with substantially reduced body weight and circulating glucose and insulin. We have already shown that these benefi cial eff ects are not reproduced by simple dietary restriction, or associated with changes in energy expenditure [ 3 ] . Therefore, in this study we examined the impact of (pGlu-Gln)-CCK-8 treatment on the expression of key hypothalamic genes involved in energy balance, in an attempt to elucidate possible underlying mechanisms. Treatment with (pGlu-Gln)-CCK-8 for 16 days in high fat fed mice resulted in an unexpected increase in NPY gene expression compared to both lean control and saline treated high fat mice. As such, increased NPY activity is generally associated with elevated food intake. Thus, normal rats receiving hypothalamic injections of an NPY expression vector display a 2-fold increase in NPY mRNA expression and develop signifi cantly increased energy intake leading to obesity [ 5 ] . However, in agreement with the current study, hypothalamic NPY mRNA expression is decreased in CCK 1 R knockout rats [ 6 ] . This suggests that modulation of hypothalamic NPY signaling may play a role in CCKmediated eff ects on energy intake. A functional interaction between CCK 1 R signaling and NPY has been proposed through experiments revealing co-localization of CCK 1 R and NPY immunoreactivity in the hypothalamus [ 6 ] . However, we observed no mice. *p < 0.05, **p < 0.01, and ***p < 0.001 compared to high fat group signifi cant change in CCK 1 R gene expression in the current study, although there was a tendency towards increased CCK 1 R expression, which may have reached signifi cance with a larger sample number. POMC neurons in the NTS are activated by CCK and this eff ect is blocked by CCK antagonists [ 7 ] . This CCK/POMC eff ect is thought to be dependent on MC4R signaling pathways in the hypothalamus [ 8 ] . Indeed, MC4R knockout mice have delayed meal termination and reduced sensitivity to CCK [ 8 ] . Moreover, the melanocortin MC4R antagonist, SHU9119, prevents CCKinduced suppression of feeding [ 7 ] . Interestingly, POMC mRNA expression is increased in CCK 1 R knockout rats [ 6 ] . Thus, melanocortin signaling pathways appear to be fundamental for the satiety eff ect of CCK. In agreement, the present study has shown signifi cant decreases in the hypothalamic expression of both POMC and MC4R in response to twice daily intraperitoneal injection with (pGlu-Gln)-CCK-8. We also assessed the eff ect of (pGlu-Gln)-CCK-8 treatment on the expression of receptors for leptin and GLP-1, since both compounds have well characterized eff ects on energy homeostasis and are known to interact with CCK [ 9 , 10 ] . However, there were no changes in hypothalamic gene expression of either receptor in the current study.
In conclusion, the present study indicates that the therapeutic effi cacy of (pGlu-Gln)-CCK-8 is associated with modulation of NPY, POMC, and MC4R gene expression in the hypothalamus. However, further studies are required to fully delineate the mechanism of action of these eff ects and the potential of stable analogues of CCK-8 as novel therapeutic agents for obesitydiabetes.
